Monday, October 26, 2015
Biodesign Institute Auditorium B105, Tempe campus [map]
Drug discovery and development is hampered by high failure rates attributed to reliance on non-human animal models employed during safety and efficacy testing. A fundamental problem in this inefficient process is that non-human animal models cannot adequately represent human biology and, more importantly, they poorly recapitulate human disease states. With the discovery of patient-specific human induced pluripotent stem (iPS) cells, the tissue engineering community is now in position to develop in vitro disease specific tissue models to be used for high content drug screening and patient specific medicine. This presentation will discuss progress in developing integrated in vitro models of human cardiac and liver tissue based on populations of normal and patient specific hiPS cells differentiated into cardiomyocytes, hepatocytes or supporting cells. The benefits of the approach include: 1) robust and reproducible platform embodies precision microengineering to create better microtissue environments; 2) precise delivery of molecules (e.g., drugs) in a computationally predictable manner; 3) ability to model human cardiomyopathy; and, 4) cost efficient and high content characterization of multi-organ cardiac liver, tissue drug response.